This preclinical evidence suggests that CB1R neutral antagonists have the potential to be efficacious and safer drugs (for instance for obesity treatment) than the therapeutically discarded CB1R inverse agonists (Figure 3). The gene discussed is CNR1; the disease is Obesity.